论文部分内容阅读
上海复星实业股份有限公司主营诊断试剂、基因工程药物、化学合成药、中成药、智能化医疗仪器等产品的开发、生产和销售。公司股票于1998年8月正式在上海证券交易所上市。1999年公司股票被美国道琼斯指数列为88个样本股之一,自1999年到2003年连续五年被中证.亚商评为“中国股票最具发展50强”之一。公司建立了上海民营企业的第一家博士后工作站和市级企业技术中心。公司之控股股东上海复星高科技(集团)有限公司被列为国务院知识产权保护试点单位,目前控股资产达25亿元,已成为国内企业技术创新的典型企业和上海科技企业的领头羊之一。
Shanghai Fosun Industrial Co., Ltd. Main diagnostic reagents, genetically engineered drugs, synthetic drugs, proprietary Chinese medicines, intelligent medical equipment and other products development, production and sales. The company's shares were officially listed on the Shanghai Stock Exchange in August 1998. In 1999, the company's stock was listed as one of the 88 sample stocks by the U.S. Dow Jones Index and was listed as one of the “Top 50 Most-Stocked Chinese Stocks” by China Securities for consecutive five years from 1999 to 2003. The company established Shanghai's first privately owned post-doctoral workstations and municipal enterprise technology center. Shanghai Fosun High-tech (Group) Co., Ltd., the controlling shareholder of the Company, is listed as a pilot unit of intellectual property protection under the State Council. Currently, the controlling assets of the company are up to 2.5 billion yuan and has become one of the leading enterprises in domestic enterprises' technological innovation and one of the leaders in Shanghai's scientific and technological enterprises .